Halozyme Therapeutics, Inc. [NASDAQ:HALO]: Analyst Rating and Earnings

Stock traders often pay close attention what Wall Street analysts have to say about a potential investment. For Halozyme Therapeutics, Inc. [HALO], the latest consensus recommendation available followed its financial results for the fiscal quarter ending in December. On average, stock market experts give HALO an Hold rating. The average 12-month price forecast for this stock is $20.18, with the high estimate being $33.00, the low estimate being $9.00 and the median estimate amounting to $20.00. This is compared to its latest closing price of $15.33.

Wall Street analysts provide their ratings on a scale of 1 to 5, and the current average score for Halozyme Therapeutics, Inc. [HALO] is sitting at 2.64. This is compared to 1 month ago, when its average rating was 2.64.

For the quarter ending in Sep-18 Halozyme Therapeutics, Inc. [HALO] generated $0.03 billion in sales. That’s 16.00% lower than the average estimate of $0.03 billion as provided by Wall Street analysts. The three indicators above suggest that on the whole, this stock is not presenting an attractive investment option, as there are too many red flags that don’t point to a high-value ROI.

Keep an eye out for the next scheduled publication date for this company’s financial results, which are expected to be released on Tue 19 Feb (In 40 Days).

Fundamental Analysis of Halozyme Therapeutics, Inc. [HALO]

Now let’s turn to look at profitability: with a current Operating Margin for Halozyme Therapeutics, Inc. [HALO] sitting at +25.58 and its Gross Margin at +90.16, this company’s Net Margin is now 16.20%. These measurements indicate that Halozyme Therapeutics, Inc. [HALO] is generating considerably more profit, after expenses are accounted for, compared to its market peers.

This company’s Return on Total Capital is 27.23, and its Return on Invested Capital has reached 20.10%. Its Return on Equity is 71.60, and its Return on Assets is 16.12. These metrics all suggest that Halozyme Therapeutics, Inc. is doing well at using the money it earns to generate returns.

Turning to investigate this organization’s capital structure, Halozyme Therapeutics, Inc. [HALO] has generated a Total Debt to Total Equity ratio of 97.11. Similarly, its Total Debt to Total Capital is 49.27, while its Total Debt to Total Assets stands at 38.92. Looking toward the future, this publicly-traded company’s Long-Term Debt to Equity is 60.06, and its Long-Term Debt to Total Capital is 30.47. This company is not leveraging its assets to take on debt, which stunts its growth and limits the ROI for investors.

What about valuation? This company’s Enterprise Value to EBITDA is 22.38 and its Total Debt to EBITDA Value is 2.43. The Enterprise Value to Sales for this firm is now 6.62, and its Total Debt to Enterprise Value stands at 0.08. Halozyme Therapeutics, Inc. [HALO] has a Price to Book Ratio of 13.88, a Price to Cash Flow Ratio of 21.02 and P/E Ratio of 49.80. These metrics suggest that this publicly-traded organization will not likely result in investment gains.

Shifting the focus to workforce efficiency, Halozyme Therapeutics, Inc. [HALO] earns $1,241,620 for each employee under its payroll. Similarly, this company’s Receivables Turnover is 16.75 and its Total Asset Turnover is 0.81. This publicly-traded organization’s liquidity data is also interesting: its Quick Ratio is 3.85 and its Current Ratio is 3.89. This company, considering these metrics, has a healthy ratio between its short-term liquid assets and its short-term liabilities, making it a less risky investment.

Performance Indicators

Let’s now turn our attention to trading performance: Halozyme Therapeutics, Inc. [HALO] has 145.35M shares outstanding, amounting to a total market cap of $2.20B. Its stock price has been found in the range of 13.24 to 21.48. At its current price, it has moved by -29.52% from its 52-week high, and it has moved 14.35% from its 52-week low.

This stock’s Beta value is currently 1.81, which indicates that it is more volatile that the wider market. This stock’s Relative Strength Index (RSI) is at 52.18. This RSI score is good, suggesting this stock is neither overbought or oversold.

Conclusion: Is Halozyme Therapeutics, Inc. [HALO] a Reliable Buy?

Shares of Halozyme Therapeutics, Inc. [HALO], on the whole, present investors with both positive and negative signals. Wall Street analysts have mixed reviews when it comes to the 12-month price outlook, and this company’s financials show a combination of strengths and weaknesses. Based on the price performance, this investment is somewhat risky while presenting reasonable potential for ROI.